These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 33619611)
21. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. Ibrahim O; Kakar R; Bolotin D; Nodzenski M; Disphanurat W; Pace N; Becker L; West DP; Poon E; Veledar E; Alam M J Am Acad Dermatol; 2013 Jul; 69(1):88-95. PubMed ID: 23591103 [TBL] [Abstract][Full Text] [Related]
22. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). Heckmann M; Ceballos-Baumann AO; Plewig G; N Engl J Med; 2001 Feb; 344(7):488-93. PubMed ID: 11172190 [TBL] [Abstract][Full Text] [Related]
23. Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin. Mirkovic SE; Rystedt A; Balling M; Swartling C Acta Derm Venereol; 2018 Jan; 98(1):103-107. PubMed ID: 28761964 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Iyer S Dermatol Surg; 2002 Sep; 28(9):822-7. PubMed ID: 12269876 [TBL] [Abstract][Full Text] [Related]
25. A preliminary study of painless and effective transdermal botulinum toxin A delivery by jet nebulization for treatment of primary hyperhidrosis. Iannitti T; Palmieri B; Aspiro A; Di Cerbo A Drug Des Devel Ther; 2014; 8():931-5. PubMed ID: 25075176 [TBL] [Abstract][Full Text] [Related]
29. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis. Rummaneethorn P; Chalermchai T Lasers Med Sci; 2020 Jul; 35(5):1179-1184. PubMed ID: 31939036 [TBL] [Abstract][Full Text] [Related]
30. Safety and prolonged efficacy of Botulin Toxin A in primary hyperhidrosis. D'Epiro S; Macaluso L; Salvi M; Luci C; Mattozzi C; Marzocca F; Salvo V; Scarnò M; Calvieri S; Richetta AG Clin Ter; 2014; 165(6):e395-400. PubMed ID: 25524193 [TBL] [Abstract][Full Text] [Related]
31. Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection. Prodan-Barbulescu C; Castiglione L; Burtic SR; Murariu M; Reddy S; Rosca O; Bratosin F; Melania Fizedean C; Krupyshev P; Enatescu I Toxins (Basel); 2024 Jan; 16(1):. PubMed ID: 38276535 [TBL] [Abstract][Full Text] [Related]
32. Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A. Skroza N; Bernardini N; La Torre G; La Viola G; Potenza C Acta Dermatovenerol Croat; 2011; 19(1):16-20. PubMed ID: 21489361 [TBL] [Abstract][Full Text] [Related]
33. Topical Botulinum Toxin Type A Liposomal Cream for Primary Axillary Hyperhidrosis: A Double-Blind, Randomized, Split-Site, Vehicle-Controlled Study. Lueangarun S; Sermsilp C; Tempark T Dermatol Surg; 2018 Aug; 44(8):1094-1101. PubMed ID: 29659406 [TBL] [Abstract][Full Text] [Related]
34. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. James E; Ellis C; Brassington R; Sathasivam S; Young CA Cochrane Database Syst Rev; 2022 May; 5(5):CD006981. PubMed ID: 35593746 [TBL] [Abstract][Full Text] [Related]
35. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Kreyden OP; Scheidegger EP Clin Dermatol; 2004; 22(1):40-4. PubMed ID: 15158544 [TBL] [Abstract][Full Text] [Related]
36. Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B. Cabreus P; Swartling C; Rystedt A J Dermatol; 2019 Oct; 46(10):874-878. PubMed ID: 31373068 [TBL] [Abstract][Full Text] [Related]
37. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Swartling C; Naver H; Lindberg M Eur J Neurol; 2001 May; 8(3):247-52. PubMed ID: 11328333 [TBL] [Abstract][Full Text] [Related]
38. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Lowe N; Campanati A; Bodokh I; Cliff S; Jaen P; Kreyden O; Naumann M; Offidani A; Vadoud J; Hamm H Br J Dermatol; 2004 Dec; 151(6):1115-22. PubMed ID: 15606505 [TBL] [Abstract][Full Text] [Related]
39. Five-year follow-up of patients treated with intra-dermal botulinum toxin for axillary hyperhidrosis. Lynch OE; Aherne T; Gibbons J; Boland MR; Ryan ÉJ; Boyle E; Egan B; Tierney S Ir J Med Sci; 2020 Aug; 189(3):1023-1026. PubMed ID: 31898163 [TBL] [Abstract][Full Text] [Related]
40. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY; J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]